News & Updates

The incidence of atopic diseases in infants born in Hong Kong has increased by 46 percent during the COVID-19 pandemic, potentially linked to altered neonatal microbiome diversity resulting from vigorous disinfection. SIM03 and SIM05, symbiotic formulae developed with the aid of artificial intelligence (AI), are shown to improve eczema severity and quality of life (QoL) in children and adults, respectively, by modulating gut microbiota.

The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.

Children and young adults with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 infection show good cardiovascular and noncardiovascular outcomes at 6 months, according to data from the long-term MUSIC study.